Quick Answer
Immix Biopharma, Inc. reported Operating Income of -$29.96 million for fiscal year 2025.
Immix Biopharma, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$29.96M | -32.1% |
| 2024 | -$22.67M | -40.5% |
| 2023 | -$16.14M | -96.4% |
| 2022 | -$8.22M | -507.9% |
| 2021 | -$1.35M | -197.9% |
| 2020 | -$453.9K | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$7.66M | -3.6% | -14.1% |
| June 30, 2025 | -$6.72M | -42.9% | -43.5% |
| March 31, 2025 | -$4.68M | +16.2% | +36.7% |
| September 30, 2024 | -$7.39M | -63.5% | -57.3% |
| June 30, 2024 | -$4.70M | -26.4% | +15.9% |
| March 31, 2024 | -$5.59M | -121.8% | -23.6% |
| September 30, 2023 | -$4.52M | -195.0% | -21.6% |
| June 30, 2023 | -$3.72M | -138.4% | -47.6% |
- Immix Biopharma, Inc. showed a decrease of -32.1% in Operating Income compared to the prior fiscal year.
- Over the 2020–2025 period, Immix Biopharma, Inc.’s operating income has declined by 6500.5% (from -$453.9 thousand to -$29.96 million).
- The most recent figure is from Immix Biopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: